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Abstract
Background: Induced pluripotent stem (iPS) cells are the novel stem cell population induced from somatic cells. It
is anticipated that iPS will be used in the expanding field of regenerative medicine. Here, we investigated whether
implantation of fetal liver kinase-1 positive (Flk-1
+) cells derived from iPS cells could improve angiogenesis in a
mouse hind limb model of ischemia.
Results: Flk-1
+ cells were induced from iPS cells after four to five days of culture. Hind limb ischemia was surgically
induced and sorted Flk-1
+ cells were directly injected into ischemic hind limbs of athymic nude mice.
Revascularization of the ischemic hind limb was accelerated in mice that were transplanted with Flk-1
+ cells
compared with control mice, which were transplanted with vehicle, as evaluated by laser Doppler blood
flowmetry. Transplantation of Flk-1
+ cells also increased expression of VEGF mRNA in ischemic tissue compared to
controls.
Conclusions: Direct local implantation of iPS cell-derived Flk-1
+ cells would salvage tissues from ischemia. These
data indicate that iPS cells could be valuable in the therapeutic induction of angiogenesis.
Background
There are increasing numbers of patients around the
world with peripheral arterial disease (PAD) [1]. Promo-
tion of collateral vessel formation and angiogenesis in
such patients is an important therapeutic strategy to
minimize tissue injury associated with severe ischemia.
Circulating endothelial progenitor cells (EPCs) have
been discovered in peripheral blood and shown to parti-
cipate in postnatal neovascularization after mobilization
from bone marrow (BM) [2,3]. Based upon those discov-
eries, we conducted therapeutic angiogenesis using auto-
logous BM-derived mononuclear cell (BM-MNC)
implantation (the TACT trial) into the ischemic muscles
in patients with critical limb ischemia [4-6]. However,
patients with very severe PAD undergoing chronic
hemodialysis or uncontrolled diabetes had poor
responses to the TACT procedure [5]. Moreover, recent
data indicate that patients with severe ischemic heart
disease and/or multiple coronary risk factors have a
reduced number of circulating EPCs, diminished angio-
genic function of their EPCs and a poor response to
angiogenic cell therapy [7-9]. Therefore, it is necessary
to discover an alternative source of stem/progenitor
cells for therapeutic angiogenesis.
Recently, novel embryonic stem (ES) cell-like pluripo-
tent stem cells were generated from mouse skin fibro-
blasts by introduction of four transcriptional factors
(Oct3/4, Sox2, Klf4, c-Myc) [10]. Termed induced pluri-
potent stem (iPS) cells, they could be used repetitively
and were capable of differentiating into various kinds of
cells as needed [11-15]. Recently, it was reported that
various cardiovascular cells could be directionally
induced from mouse and human iPS cell-derived fetal
liver kinase-1 positive (Flk-1
+) cells in vitro [11,16].
Thus, iPS cells open new possibilities for cell-based
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controversies and immune-related problems associated
with ES cells. Here, we investigated whether implanta-
tion of iPS-derived Flk-1
+ cells could augment the pro-
cess of ischemia-induced angiogenesis in vivo.
Results
Differentiation of iPS cells to Flk-1
+ cells
Undifferentiated iPS cells were cultured on collagen IV-
coated dishes with DM as described previously [11].
Firstly, we assessed the time course of Flk-1
+ cell
appearance by fluorescence-activated cell sorter (FACS).
Flk-1
+ cells appeared after 3.5 days of culture and
peaked on day 4.5 (Figure 1A). The average frequencies
of Flk-1
+ cells were 11.3% (day 3.5), 27% (day 4.5),
14.9% (day 5.5), 13.2% (day 6.5) and 6.5% (day 7.5), con-
firming a previous report [11]. Based on these findings,
we sorted Flk-1
+ cells by magnetic-activated cell sorting
(MACS) at day 4.5 of differentiation in the present
study. FACS analysis of MACS-sorted positive through
cells showed that more than 99% of these cells were
positive for Flk-1 (Figure 1B). We also found that
MACS-purified Flk-1 positive cells were sorted in not
only Nanog-GFP positive population but also Nanog-
GFP negative cell population (Figure 1B).
We also tried to characterize the Flk1
+ cells by FACS
analysis. Gated Flk1
+ cells showed CD11b negative,
CD45 negative, CD31 negative, VE-cadherin negative,
E-cadherin negative, CD34 negative or CD90 negative
(Figure 2). CD44 positive cells accounted for 39.4% of
gated Flk1+ cells, CXCR4 positive cells for 29.1%, Sca-1
positive cells for 24.8%, SSEA-1 positive cells for 23.5%
and c-kit positive cells for 8.2%. Flk1
+ cells are consid-
ered as relatively immature and still have an aspect as
heterogeneous stem cells at the upstream position.
We confirmed the expression of undifferentiated mar-
kers such as Nanog and Oct3/4 on differentiation at day
4, 5, 6 and 7 by RT-PCR (Figure 3). Undifferentiated iPS
cells markers, Nanog and Oct3/4, were strongly
expressed in early phase and started to gradually
decrease with differentiation. We also observed the tran-
sient expression of c-myc.
Figure 1 Purification of Flk-1+ cells from iPS cells. A) Flk-1 expression profiles from 3.5 days to 7.5 days of cultivation as determined by flow
cytometric analysis. (* p < 0.05 Day4.5 vs Day3.5, 5.5, 6.5 and 7.5). B) FACS analysis of pre and post MACS-sorted Flk-1
+ cells at day 4.5. More
than 99% of enriched cells were positive for Flk-1. Some of these purified Flk-1
+ cells were positive for Nanog-GFP.
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Page 2 of 10Augmentation of ischemia-induced angiogenesis by Flk-1
+
cells derived from iPS cells
We examined whether in vivo implantation of Flk-1
+
cells derived from iPS cells could augment ischemia-
induced angiogenesis using a mouse model of hind limb
ischemia. KSN athymic nude mice underwent surgical
induction of unilateral hind limb ischemia. Sorted Flk-1
+
cells (6×10
4cells/mouse) or control PBS were injected
into adductor muscles in the ischemic limb at post-
operative day 1 (Figure 4A). All mice survived from sur-
gery and appeared healthy during the follow-up period.
Body weight and blood pressure did not differ among
the groups. We show the representative LDBF images of
hind limb blood flow of recipient mice just after the sur-
gery and at the different time points after surgery (Fig-
ure 4B). In control mice, hind limb perfusion fell
precipitously after surgery, increased to 20 - 30% of the
nonischemic limb by day 3, and increased to 40-50% of
the nonischemic limb by day 14 (Figure 4C). However,
mice transplanted with Flk-1
+ cells showed significant
increases in hind limb blood relative to control at 3, 7
and 14 days after hind limb surgery (Figure 4B,C). We
next assessed dose-dependency of cell transplantation at
7 days after surgery. Smaller doses of cells (2 × 10
4
cells/mouse) also yielded improvements in blood perfu-
sion (Figure 4D). However, mice treated with 2 × 10
3
cells did not achieve a significant improvement in blood
perfusion in the ischemic limb compared to control
mice (Figure 4D).
Implanted Flk-1
+ cells augmented the expression of VEGF
in ischemic tissues
We investigated whether implantation of Flk-1
+ cells
would up-regulate VEGF mRNA expression in ischemic
hind limb tissues in chronological order. At postopera-
tive days 3 and 7, VEGF mRNA expression increased
significantly in mice transplanted with Flk-1
+ cells (6 ×
10
4 c e l l s )c o m p a r e dt ot h a to fc o n t r o lm i c e( F i g u r e5 ) .
Figure 2 Characterization of Flk1+ cells. Differentiated iPS cells were analyzed by FACS. Differentiated iPS cells were stained with Flk1-APC
and additional cell marker (c-kit, Sca-1, CD11b, CD31, VECAD, CD34, CD44, CD45, CD90, SSEA-1, CXCR4 and ECAD). Additional cell marker was
analyzed after gating Flk1
+ cells. Red line shows the result of the negative control and Blue line shows the result of the sample stained by each
antibody.
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4 cells/mouse) also slightly
increased VEGF mRNA expression. At day 14, there was
no significant difference between the groups. However,
the dose-dependency for expression of VEGF mRNA
was apparent.
We next examined the synthesis of basic FGF, HGF and
IGF in ischemic muscle after cell transplantation by
real-time PCR. There were no significant difference in
these mRNA levels between mice transplanted with Flk-1
+
cells and control mice (Figure 5).
Tracing Flk-1
+ cells in vitro and at chronic phase in vivo
We examined whether Flk-1
+ cells could be incorpo-
rated into the vascular network in vitro. Figure 6A
shows representative photographs of PKH26-labeled
Flk-1
+ iPS cells and HUVECs after 24 hours of co-cul-
ture on a Matrigel. Incorporation of Flk-1
+ iPS cells
(red) into the network structures was confirmed.
Using PKH26-labeled Flk1
+ cells, we examined
whether in vivo implanted Flk-1
+ cells survived and dif-
ferentiated into vascular endothelial cells in ischemic tis-
sues (Figure 6B). Transplanted PKH26-positive cells
were found in the ischemic area even at postoperative
day 21. Immunofluorescence histology revealed that
some of the PKH26-positive cells were co-stained with
the endothelial cell marker CD31 (Figure 6B). These
results indicated that implanted Flk-1
+ cells contributed
to vascular structure formation at postoperative day 21.
We could not detect any tumors in the mice trans-
planted with Flk-1
+ (6 × 10
4) cells through the 60 days
after transplantation (n = 3).
Discussion
The present study provides evidence that implantation
of Flk-1
+ cells differentiated from mouse iPS cells pro-
mote angiogenesis in a well-established hind limb ische-
mia model. In the model, no tumors were observed.
Mice transplanted with these cells displayed rapid recov-
ery of limb blood perfusion, which was accompanied by
a rapid increase in VEGF mRNA levels in the ischemic
tissues.
Recently, preclinical studies had validated the concept
of “cell therapy for ischemic disease” using stem/pro-
genitor cells to repair and regenerate vascular cells in
patients with severe ischemic cardiovascular disease
[4,17]. However, collection of somatic stem cells in suffi-
cient numbers for cell therapy is difficult and may
require invasive procedures such as bone marrow
aspiration or resection of th el i v e ro rp a n c r e a s .A d d i -
tionally, problems of utilizing somatic stem cell is that
(1) the number of somatic stem cell is very limited in
general, (2) the implanted progenitor cells have low
functions of mobilization capacity from bone marrow as
well as angiogenic potentials in patients with multiple
risk factors for arteriosclerosis [7-9,18]. On the other
hand, iPS cells have an unlimited ability for self-renewal
and expansion [10,19]. Thus, it might be possible to col-
lect large numbers of cells following cultivation in vitro
while maintaining its undifferentiated phenotype. iPS
cells can also be differentiated into various kinds of cells
as needed [11-16]. In addition, autologous iPS cells can
circumvent the ethical controversy associated with ES
cell and reduce immune-related problems [20]. Thus,
iPS cells may have superiority for vascular regenerative
medicine compared to ES cells and somatic stem/pro-
genitor cells.
Therapeutic angiogenesis is likely mediated by multi-
ple angiogenic cytokines released from implanted cells
and host muscle tissues such as VEGF, bFGF and HGF
rather than by direct differentiation of transplanted cells
into mature endothelial cells [21-23]. Consistent with
this notion, our study showed that implanted Flk-1
+
Figure 3 Time course RT-CPR in vitro. The expression of Flk-1
was peaked at Day5 from differentiation. Undifferentiated iPS cells
markers, Nanog and Oct3/4, were strongly expressed in early phase
and started to gradually decrease with differentiation. We also
observed the transient expression of c-myc at Day4 and Day5.
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sion of VEGF in ischemic tissues. On the other hand,
the expression of bFGF, HGF or IGF was not affected in
this study. Enhanced VEGF activity would directly affect
hind limb blood flow.
Recently, Narazaki and coworkers showed that Flk-1
+
cells derived from mouse iPS cells could differentiate
into both endothelial and mural cells and reproduce the
vascular regeneration process [11]. In the present study,
we confirmed incorporation of Flk-1
+ cells generated
from iPS cells into vascular network structures in vitro.
In addition, it was shown that implanted Flk-1
+ cells
were successfully incorporated into capillary networks in
the ischemic tissues. Therefore, Flk-1
+ cells generated
from iPS cells might stimulate angiogenesis not only by
a paracrine action of cytokines but also by a direct side
supply of endothelial cells. These findings are encoura-
ging since it is possible that implantation of iPS cell-
derived Flk-1+ cells could construct de novo vessels in
ischemic tissues, consistent with postnatal vasculogen-
esis. Further studies will be needed to clarify the differ-
entiation capacity of these cells.
Recently, two studies reported the usefulness of Flk-1
+ cells for promoting angiogenesis in vivo [24,25].
Transplantation of human cord blood-derived Flk-1
+/CD34
+ cells could salvage ischemic tissue in severe
combined immune deficiency mice [24]. When Flk-1
+
cells generated from ES cells were directly injected
into the heart, significant improvement in cardiac
function was observed in doxorubicin induced cardio-
myopathy, and this was accompanied by an increase in
capillary density [25].
Figure 4 Effects of cell transplantation on blood flow recovery in the ischemic hind limb.A )S t r a t e g yt op u r i f yF l k - 1
+ cells and to
transplant them into ischemic hind limb tissues. B) Representative LDBF images. A low perfusion signal (dark blue) was observed in the ischemic
left hind limb of control mice, whereas high perfusion signals (white to red) were detected in Flk-1
+ cell-transplanted animals (6 × 10
4 cells) on
postoperative days 3, 7 and 14. C) Quantitative analysis of the ischemic/nonischemic limb LDBF ratio on pre (Day-1) and post operative days 0, 3,
7 and 14 (n = 4). *p < 0.05 Flk1
+ cells (6×10
4) injected mice vs. control mice. D) Cell dose-dependent effect of transplantation seven days after
surgery. Flk-1
+ cells (2 × 10
3,2×1 0
4 or 6 × 10
4 cells) or PBS as a control were injected into the ischemic limb at postoperative day 1 (n = 4/
each group, **p < 0.05 2×10
4 or 6×10
4 vs. control mice).
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regard to the unexpected lack of difference in VEGF
expression in day 14, self-healing and supplementary
effect by iPS may spontaneo u s l ya t t e n u a t ea r o u n d1 4
days after transplantation. One study showed that dou-
ble immunolabeling for BrdU and CD-31 in ischemic
versus normal murine hindlimbs established that
endothelial cell proliferation peaks at 7 d (1,235 ± 254
versus 8 ± 14 BrdU-positive cells/mm
2 for the ischemic
versus normal limbs, respectively, P < 0.001); prolifera-
tive activity is then subsequently reduced at days 14 and
21 [26]. However, detailed biochemical and cellular stu-
dies are required to better understand the underlying
mechanism of these conditions.
Secondly, the KSN nude mice were used for this study
to avoid immunological rejection of the injected iPS
cells, because the genetic background of the MEFs for
iPS generation in this study was 75% DBA, 12.5%
C57BL/6 and 12.5% 129S4 [27]. KSN nude mice were
mostly dead within three month by intestinal infections.
We could not detect formation of any tumors in the
mice transplanted Flk-1
+ cells at least until post-operative
day 60. Because more than 99% of MACS-sorted cells
were Flk1
+, the contamination of undifferentiated cells-
into injected cells was very rare. The present study indi-
cated the possibility of therapeutic use of iPS cells.
However, we always need very careful observation for
tumor formation in any transplantation studies using iPS
cells in the future.
Conclusion
In conclusion, direct local implantation of mouse iPS
cell-derived Flk-1
+ cells has augmented ischemia-
induced angiogenesis in a mouse model. This suggests
t h a ti P Sc e l l sw o u l db eap o t e n t i a lc a n d i d a t ef o ru s ei n
therapeutic angiogenesis.
Methods
Reagents
Allophycocyanin (APC) conjugated anti-mouse Flk-1,
Phycoerythrin (PE) conjugated anti-mouse Sca-1 and
PE-CD44 antibodies were purchased from eBioscience
Figure 5 Flk-1+ cell implantation stimulated VEGF, basic FGF, HGF and IGF expression in ischemic tissue. VEGF, basic FGF, HGF and IGF
synthesis in ischemic hind limb muscles was determined by real-time RT-PCR following transplantation of the Flk-1
+ cells (2 × 10
3,2×1 0
4 or 6
×1 0
4 cells) or PBS-injection as the control(CNT). Results are expressed as the level of VEGF, basic FGF, HGF and IGF mRNA to day three control.
GAPDH mRNA levels were used as the internal control. *P < 0.05 6×10
4 vs. CNT at each day (n = 4 in each groups). N.S. = not significant
difference between groups at same day.
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purchased from Miltenyi Biotec (Bergisch Gladbach,
Germany). PE conjugated anti-mouse CD11b, PE-CD45,
PE-CD117(c-kit), PE-CD31, PE-CXCR4, Fluorescein
isothiocyanate (FITC) conjugated anti-mouse CD34,
FITC-CD90 and CD31 monoclonal antibodies were pur-
chased from BD Pharmingen (San Diego, California). PE-
SSEA1 antibody was purchased from R&D Systems (Min-
neapolis, Minnesota). PE-VE-cadherin antibody was pur-
chased from Santa Cruz Biotechnology (Santa Cruz,
Figure 6 Tracking Flk-1
+ cells in vitro and at chronic phase in vivo. A) Tube formation assay in vitro. PKH26 red-labeled Flk-1
+ iPS cells were
co-cultured with HUVECs for 24 hours on Matrigel. iPS cells (red) were confirmed to be incorporated into network structures. The bar indicates
200 μm. B) Double fluorescence staining of CD31 (green) and PKH26 (red) in ischemic adductor muscles on postoperative day 21. Co-localization
is indicated by yellow in the merged images (magnification, ×400; bar indicates 50 μm). Flk-1
+ cells (6 × 10
4 cells) were stained with PKH26 red
and then injected into ischemic adductor muscles. Double positive cells (▲) and single positive PKH26 cells(↑) are indicated.
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body was purchased from Cell Signaling Technology
(Danvers, Massachusetts). PKH26 Red Fluorescent Cell
Linker Kit was purchased from SIGMA-ALDRICH (St
Louis, Missouri).
Cell Culture
Germline competent mouse iPS cell lines “iPS-MEF-Ng-
20D-17” generated from mouse embryonic fibroblasts by
introducing the four factors(Oct3/4, Sox2, Klf4 and the
c-Myc mutant c-Myc(T58A) with the use of retroviral
vectors were provided by Riken Cell Bank with the per-
m i s s i o no fD r .S .Y a m a n a k a[ 1 0 , 2 7 ] .i P S - M E F - N g - 2 0 D -
17 cell is carrying Nanog promoter-driven GFP/IRES/
puromycin-resistant gene (Nanog-iPS cells). iPS cells
were maintained in Dulbecco’s modified Eagle’s medium
(Invitrogen, Van Allen Way Carlsbad, California) con-
taining 10% Knockout Serum Replacement (KSR)(Invi-
trogen), 1% fetal bovine serum (FBS), nonessential
amino acids, 5.5 mmol/L 2-mercaptoethanol, 50 U/mL
penicillin, and 50 mg/mL streptomycin on feeder layers
of mytomycin-C-treated mouse embryonic fibroblast
cells stably releasing leukemia inhibitory factor (LIF).
Cell differentiation was induced as described previously
[11]. In brief, differentiation medium (DM) (a-minimum
essential medium (Invitrogen) supplemented with 10%
FBS and 5 × 10
-5 mol/L 2-mercaptoethanol) was used
for iPS cell differentiation. Flk-1
+ mesodermal cells were
induced by 96 to 108 hr culture of iPS cells (plated at
1.7 × 10
3 cells/cm
2)i nD Mi nt h ea b s e n c eo fL I Fo n
type IV collagen-coated dishes (ASAHI GLASS CO.,
LTD, Tokyo, Japan).
Cell separation and analysis
Cultured cells were harvested after induction of Flk-1
+
cells by 96 to 108 hr culture in DM on type IV col-
lagen-coated dishes. Induced cells were stained with
APC conjugated anti-mouse Flk-1 antibody. Flk-1
+ cells
were sorted with a magnetic cell separation system and
purity was confirmed by flow cytometric analysis (BD
FACS Canto, BD, Franklin Lakes, New Jersey). For the
detailed characterization, induced cells were stained
with APC conjugated anti-mouse Flk-1 antibody and
additional antibody (CD11b, CD44, CD45, CD117, Sca-1,
SSEA-1, E-cadherin, CXCR4, CD31, VE-cadherin, CD34
and CD90). Stained cells were analyzed by BD FACS
Canto.
Tube formation assay and incorporation of Flk-1
+ iPS cells
The formation of vascular-like structures by Flk-1
+ iPS
cells on growth factor-reduced Matrigel (BD Bios-
ciences, Bedford, Massachusetts) was performed as
described previously [28]. Briefly, iPS positive cells
(labeled with the PKH26 Red Fluorescent Cell Linker
Kit [SIGMA-ALDRICH, St Louis, Missouri]) and
HUVEC(Cambrex Bio Science Walkersville, Inc., Charles
City, Iowa) were seeded at a ratio of 1:1 on coated plates
at 3 × 10
4 cells/cm
2 in EBM-2 medium containing
EGM-2(LONZA, Basel, Switzerland) and incubated at
37°C for 24 h. Network formation and Flk-1
+ iPS cell
incorporation were assessed using an inverted phase
contrast microscope (Biozero BZ8000, KEYENCE Japan,
Osaka, Japan).
Mouse model of hind limb ischemia and cell
transplantation
Male KSN athymic nude mice were used for this study.
Study protocols were approved by the Institutional
Animal Care and Use Committee (IACUC) of Nagoya
University School of Medicine. Mice, ages 8 to 12
weeks, were subjected to operative unilateral hind limb
ischemia under anesthesia with sodium pentobarbital
(50 mg/kg i.p.). In this model, the entire left femoral
artery and vein were excised surgically [29]. Before
surgery and on postoperative days three, seven, 14, and
21, body weight and systolic blood pressure were
determined using a tail-cuff pressure analysis system in
the conscious state. Flk-1
+ cells (2 × 10
3,2×1 0
4 or 6
×1 0
4 cells/mouse) or PBS as a control were injected
into four different sites of adductor muscles in the
ischemic limb on postoperative day one. To trace
transplanted cells in the ischemic tissues, sorted Flk1
+
cells were labeled with a PKH26 Red Fluorescent Cell
Linker Kit and then injected into ischemic adductor
muscles. Implanted cells were evaluated by immuno-
histochemical analysis 21 days after cells implantation.
The signals were detected and analyzed by fluores-
cence microscopy.
Laser Doppler blood flow analysis
Hindlimb blood flow was measured using a laser Dop-
pler blood flow (LDBF) analyzer (Moor LDI; Moor
Instruments, Devon, United Kingdom). LDBF analysis
was performed on legs and feet. Blood flow was dis-
played as changes in the laser frequency using different
color pixels. After scanning, stored images were ana-
lyzed to quantify blood flow. To avoid data variations
due to ambient light and temperature, hindlimb blood
f l o ww a se x p r e s s e da st h er a t i oo fl e f t( i s c h e m i c )t o
right (nonischemic) LDBF in a same mouse according
to previous studies [26,29-33]. In addition, in this study,
the each ratio of left (ischemic) to right (nonischemic)
LDBF was normalized to the each day-1(pre surgery)
LDBF value.
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time Reverse transcriptase-polymerase chain reaction
Total RNA was isolated from cultured iPS cells using TRI-
zol Reagent (Invitrogen Life Technologies, Carlsbad, CA).
Total RNA from ischemic muscles was extracted using the
of FastRNA Pro Green Kit. (MP Biomedicals, Solon,
Ohio). The cDNA was produced using oligo-dT primers
and superscript II reverse transcriptase (superscript II,
Invitrogen). The cDNA was diluted with DNase-free water
at a concentration of 10 ng/μl. RT-PCR was performed
using the Ex-Taq PCR kit (Takara, Otsu, Japan) according
to the manufacturer’s instructions.
Real-time reverse transcriptase-polymerase chain reac-
tion (real-time RT-PCR) was performed using 1 μg
cDNA in the Mx3000P Real-Time PCR System (Strata-
gene, Agilent Technologies, Santa Clara, California)
using SYBR Green I as a double-stranded DNA-specific
dye according to the manufacturer’s instructions
(Applied Biosystem, Foster City, California).
Primers were as follows: forward 5’-CAGGCTGCTG-
TAACGATGAA-3’ (Location: Exon3, Melting Tempera-
ture:60.01°C) and reverse 5’-GCATTCACATCTGC
TGTGCT-3’ (Location: Exon4, Melting Tempera-
ture:60.02°C), Product size: 140 bp for murine VEGF.; for-
ward 5’-GGCGGTGGTGACAGTATCTT-3’ (Location:
Exon3, Melting Temperature:60.00°C) and reverse 5’-
GTCACTGACAGAGGCGATGA-3’ (Location: Exon4,
Melting Temperature:59.99°C), Product size: 162 bp for
murine Flk-1.;forward 5’-CCAATCAGCTTGGGCTA-
GAG-3’ (Location: Exon5, Melting Temperature:59.97°C)
and reverse 5’-CTGGGAAAGGTGTCCCTGTA-3’ (Loca-
tion: Exon6, Melting Temperature:59.96°C), Product size:
129 bp for murine Oct3/4.;forward 5’-AAGTACCT-
CAGCCTCCAGCA-3’ (Location: Exon3, Melting Tem-
perature:60.01°C) and reverse 5’-GGGGATAGCTG
CAATGGATG-3’ (Location: Exon5, Melting Tempera-
ture:62.66°C), Product size: 199 bp for murine Nanog.;for-
ward 5’-TCCTGTACCTCGTCCGATTC-3’ (Location:
Exon2, Melting Temperature:60.07°C) and reverse 5’-
GGTTTGCCTCTTCTCCACAG-3’ (Location: Exon3,
Melting Temperature:59.84°C), Product size: 195 bp for
murine c-myc.;forward 5’-AGTGTGACGTTGA-
CATCCGT-3’ (Location: Exon5, Melting Tempera-
ture:59.02°C) and reverse 5’-GCAGCTCAGTAACAG
TCCGC-3’ (Location: Exon7, Melting Temperature:61.15°
C), Product size: 298 bp for murine beta actin.; forward 5’-
AACTTTGGCATTGTGGAAGG-3’ (Location: Exon3,
Melting Temperature:59.97°C), and reverse 5’-ACA-
CATTGGGGGTAGGAACA-3’(Location: Exon3, Melting
Temperature:60.09°C), Product size: 223 bp for murine
GAPDH.; forward 5’-AGCGGCTCTACTGCAAGAAC-
3’(Location: Exon1, Melting Temperature:59.79°C), and
reverse 5’-GCCGTCCATCTTCCTTCATA-3’(Location:
Exon4, Melting Temperature:60.04°C), Product size: 183
bp for murine FGF2.; forward 5’-GGCAGCTATAAAGG-
GACGGTA-3’ (Location: Exon5, Melting Tempera-
ture:60.46°C), and reverse 5’-CTTCTTCCCCTCGAGGA
TTT-3’ (Location: Exon6, Melting Temperature:59.65°C),
Product size: 154 bp for murine HGF.
Analyses of mRNA levels of VEGF were normalized to
GAPDH as the internal control and expressed relative
to the quantity of VEGF mRNA at day three in ischemic
adductor muscle injected with PBS (day three control).
Statistical Analysis
All data were obtained from at least three independent
experiments. Statistical analysis of the data was per-
formed using Student’s t test or two-way ANOVA. P <
0.05 was considered significant. All data are shown as
means ± SEM.
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